Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Infect Drug Resist ; 14: 1845-1853, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34040398

RESUMO

PURPOSE: The cost-effectiveness of different guideline-concordant antimicrobial regimens for elderly patients with community-acquired pneumonia (CAP) was rarely discussed. This study attempts to explore the most appropriate cost-effectiveness of guideline-concordant antimicrobial regimen for elderly patients with CAP in general wards. PATIENTS AND METHODS: This was a multicenter, retrospective, 4:2:1 matched study enrolling 511 elderly patients with CAP hospitalized in general wards. Two hundred ninety-two patients prescribed with ß-lactam monotherapy (group A), 146 patients prescribed with fluoroquinolone monotherapy (group B) and 73 patients prescribed with ß-lactam/macrolide combination therapy (group C). Clinical outcomes and medical costs were analyzed by χ 2 test for categorical variables or Kruskal-Wallis H-test for continuous variables. RESULTS: There were no statistical differences in imaging features, etiology and complications during hospitalization among these three groups. The rates of clinical failure occurrence, in-hospital mortality, 30-day mortality and 60-day mortality also had no significant differences among group A, B and C patients; however, the median length of stay (LOS) in group A patients was 12.0 days, which was significantly higher than that in group B and C patients (both 10.0 days, p<0.02). The median total, drug, and antibiotic costs for one elderly CAP episode in group B patients were RMB 10368.4, RMB 3874.8, and RMB 1796.3, respectively, which were significantly lower than those in group A and C patients (p<0.01). CONCLUSION: Non-inferiority of clinical failure occurrence and short-term mortality was observed in different guideline-concordant antimicrobial regimens for elderly patients with CAP in general wards; however, the median LOS and hospitalization-associated costs for one elderly CAP episode with fluoroquinolone monotherapy were significantly lowest, and this strategy was considered to be the most cost-effective strategy in general wards.

2.
BMJ Open ; 8(2): e018709, 2018 02 15.
Artigo em Inglês | MEDLINE | ID: mdl-29449294

RESUMO

OBJECTIVES: To describe the clinical characteristics and management of patients hospitalised with community-acquired pneumonia (CAP) in China. DESIGN: This was a multicentre, retrospective, observational study. SETTING: 13 teaching hospitals in northern, central and southern China from 1 January 2014 to 31 December 2014 PARTICIPANTS: Information on hospitalised patients aged ≥14 years with radiographically confirmed pneumonia with illness onset in the community was collected using standard case report forms. PRIMARY AND SECONDARY OUTCOME MEASURES: Resource use for CAP management. RESULTS: Of 14 793 patients screened, 5828 with radiographically confirmed CAP were included in the final analysis. Low mortality risk patients with a CURB-65 score 0-1 and Pneumonia Severity Index risk class I-II accounted for 81.2% (4434/5594) and 56.4% (2034/3609) patients, respectively. 21.7% (1111/5130) patients had already achieved clinical stability on admission. A definite or probable pathogen was identified only in 12.7% (738/5828) patients. 40.9% (1575/3852) patients without pseudomonal infection risk factors received antimicrobial overtreatment regimens. The median duration between clinical stability to discharge was 5.0 days with 30-day mortality of 4.2%. CONCLUSIONS: These data demonstrated the overuse of health resources in CAP management, indicating that there is potential for improvement and substantial savings to healthcare systems in China. TRIAL REGISTRATION NUMBER: NCT02489578; Results.


Assuntos
Antibacterianos/uso terapêutico , Infecções Comunitárias Adquiridas/terapia , Recursos em Saúde/estatística & dados numéricos , Hospitalização , Uso Excessivo dos Serviços de Saúde , Pneumonia/terapia , Índice de Gravidade de Doença , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/economia , China , Infecções Comunitárias Adquiridas/tratamento farmacológico , Infecções Comunitárias Adquiridas/economia , Infecções Comunitárias Adquiridas/microbiologia , Feminino , Custos de Cuidados de Saúde , Hospitalização/economia , Hospitais de Ensino , Humanos , Tempo de Internação/economia , Masculino , Uso Excessivo dos Serviços de Saúde/economia , Pessoa de Meia-Idade , Pneumonia/tratamento farmacológico , Pneumonia/economia , Pneumonia/microbiologia , Pseudomonas/crescimento & desenvolvimento , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/economia , Infecções por Pseudomonas/microbiologia , Infecções por Pseudomonas/terapia , Estudos Retrospectivos , Fatores de Risco , Inquéritos e Questionários , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA